Drug intelligence / Profile preview

Calm

Development stage: Unknown
Lead developer: Dosist
Modality: Small Molecules
Administration: Inhalation

Overview

**Calm** is a dosist dose-controlled cannabis formulation marketed in inhaled vaporizer-pen formats for relaxation and relief of anxiety and tension. The vape formulation combines cannabis-derived tetrahydrocannabinol and cannabidiol with plant-derived terpenes; a commonly listed historical vape composition is a 1:6 THC:CBD ratio. dosist describes Calm as one of its cannabinoid-and-terpene core need-state formulations, while the brand has also used the Calm name for a distinct THC:CBD gummy formulation. ([dosist.com](https://dosist.com/dose-pens/))

Brand names: Calm

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on Calm.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calm.

Explore the full profile